Search Results for "Recall Promus Heart Stent"

13:21 EDT 24th May 2015 | BioPortfolio

Matching Channels

BioMimics 3D™ Stent

Veryan has developed three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The initial objective was to investigate the presen...

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Aorfix

Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anat...

Heart Transplantation

Heart Failure HF

Matching News

Added Value of Biodegradable-Polymer DES Questioned

Researchers said they saw no advantage against late stent thrombosis for the biodegradable-polymer Nobori stent. In a different study, the Synergy stent was noninferior to the Promus Prime DES. Hear...

Boston Scientific's Synergy stent passes Evolve II trial

Boston Scientific's Synergy stent passed the Evolve II trial, where it was put against drug-eluting stent Promus, the company -More- 

Heart Sync's defibrillator electrode recall labeled Class I by FDA

A recall initiated by Michigan firm Heart Sync on Nov.  -More- 

Boston Scientific stent succeeds in study aimed at U.S. approval

CHICAGO, Nov 19 (Reuters) - Boston Scientific Corp's next generation Synergy heart stent succeeded in a pivotal study that will be used to seek U.S. and Japanese approval of the device, according to d...

FDA labels Maquet's cardiac closure device recall as Class I

A recall involving Maquet Cardiovascular's TigerPaw II, a device intended to occlude the left atrial appendage of the heart t -More- 

Causes, assessment, and treatment of stent thrombosis—intravascular imaging insights

Stent thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In this Review, Ong and Jang discuss the use of intra...

Low stent thrombosis rates with primary PCI, regardless of antithrombotic choice

(EuroPCR) Stent thrombosis following urgent angioplasty for acute heart attack occurred in less than 1 percent of patients in a large, 'real-world' registry, regardless of whether the antithrombotic t...

Half of heart stent patients don’t follow oral antiplatelet therapy regime as prescribed

A recent survey has found that 52% of 275 ACS patients who were currently taking an oral antiplatelet have missed taking or changed the way they take it... The post Half of heart stent patients don...

Matching PubMed Articles

Neoatherosclerosis causing edge in-stent restenosis: optical coherence tomography findings.

A patient presenting with 'edge' in-stent restenosis 12 years after the implantation of a bare-metal stent in the mid-left anterior descending coronary artery is described. Optical coherence tomograph...

Outcomes of everolimus-eluting stent incomplete stent apposition: a serial optical coherence tomography analysis.

The aim of the present study was to evaluate the natural course of acute incomplete stent apposition (ISA) after second-generation everolimus-eluting stent (EES) when compared with first-generation si...

PLATINUM China: A prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.

Objectives: The PLATINUM China clinical trial evaluated the safety and effectiveness of the thin-strut, everolimus-eluting, platinum-chromium PROMUS™ Element™ stent (PtCr-EES) (Boston Scientific, ...

Spectral Analysis Related to Bare-Metal and Drug-Eluting Coronary Stent Implantation.

Background: The autonomic nervous system plays a central role in cardiovascular regulation; sympathetic activation occurs during myocardial ischemia. Objective: To assess the spectral analysis of hear...

Bioresorbable vascular scaffold for coronary in-stent restenosis: A novel concept.

The management of patients with significant in-stent restenosis (ISR) with drug-eluting stent is still not well defined. Various treatment modalities include plain old balloon angioplasty (POBA), meta...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement